SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.950
-0.030 (-1.52%)
At close: Mar 6, 2026
SinoMab BioScience Revenue
SinoMab BioScience had revenue of 9.78M CNY in the half year ending June 30, 2025, with 15.50% growth. This brings the company's revenue in the last twelve months to 5.73M. In the year 2024, SinoMab BioScience had annual revenue of 2.03M with 48.42% growth.
Revenue (ttm)
5.73M CNY
Revenue Growth
+48.42%
P/S Ratio
430.87
Revenue / Employee
93.89K CNY
Employees
61
Market Cap
2.70B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.03M | 661.00K | 48.42% |
| Dec 31, 2023 | 1.37M | -2.67M | -66.15% |
| Dec 31, 2022 | 4.03M | -22.63M | -84.87% |
| Dec 31, 2021 | 26.66M | 13.90M | 108.91% |
| Dec 31, 2020 | 12.76M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.01B |
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| BioDlink International Company | 1.17B |
| Medtide | 546.29M |
| Qyuns Therapeutics | 351.04M |
| Antengene Corporation | 92.43M |